Sana Biotechnology: A Shot At DiabetesSeeking Alpha · Oct 13, 2026
Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 14, 2026
Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha · Sep 10, 2026
Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha · Sep 10, 2026
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PRNewsWire · Sep 7, 2026
Sana Biotechnology to Present at September 2026 Investor ConferencesGlobeNewsWire · Sep 1, 2026Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.15 | -$0.22 | Miss |
| May 11, 2026 | -$0.15 | -$0.14 | Beat |
| Mar 3, 2026 | -$0.13 | -$0.16 | Miss |
| Nov 6, 2025 | -$0.18 | -$0.15 | Beat |
| Aug 11, 2025 | -$0.20 | -$0.39 | Miss |
| May 8, 2025 | -$0.22 | -$0.20 | Beat |